Brendan Dickinson leads Canaan's fintech practice with a focus on infrastructure and platform companies rather than consumer apps, backing firms that build underlying rails and tooling for financial services while framing his investing thesis around changing the world with code. He has developed a structured framework for fintech investing that categorizes opportunities across infrastructure, distribution, and new financial products, and is recognized as a specialist in marketplace lending and online credit evolution rather than generic fintech themes.

• A focus on precise financial metrics and honest business modeling, particularly within fintech. He expresses frustration when founders try to misclassify interest income as annual recurring revenue or conflate lending valuations with SaaS multiples, suggesting a need for strict financial clarity when pitching him.
• Skepticism regarding AI privacy and permission levels. He questioned why users would grant an AI full access to sensitive accounts like email when they wouldn't trust a human assistant with that same level of access, implying that founders building agents need to have a strong answer for security and trust.
• Interest in startups capitalizing on major regulatory shifts or deep technical moats. He highlighted an investment in a Brazilian company called Marvin specifically because the team was positioned to take advantage of a massive regulatory change in that market, and separately praised a quantum computing investment based on the founding team's history of invention.
• Valuation of deep conviction over excessive diligence. He reflected that his biggest missed opportunities were actually deals where he initially wanted to say yes but ended up overthinking the decision, indicating he respects founders who can help him maintain his initial enthusiasm.
• Appreciation for collaborative firm culture and partner success. He frequently champions his colleagues at Canaan, such as celebrating a partner who incubated a pediatric cancer treatment company that received FDA approval, suggesting he operates well within a supportive, team-based partnership structure.